KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $930.7 million.

  • BioNTech SE's Current Deferred Revenue rose 12484.71% to $930.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $930.7 million, marking a year-over-year increase of 12484.71%. This contributed to the annual value of $315.1 million for FY2024, which is 2650.26% down from last year.
  • BioNTech SE's Current Deferred Revenue amounted to $930.7 million in Q3 2025, which was up 12484.71% from $1.1 billion recorded in Q2 2025.
  • BioNTech SE's Current Deferred Revenue's 5-year high stood at $1.1 billion during Q2 2025, with a 5-year trough of $48.9 million in Q1 2023.
  • Moreover, its 5-year median value for Current Deferred Revenue was $356.1 million (2021), whereas its average is $429.6 million.
  • Per our database at Business Quant, BioNTech SE's Current Deferred Revenue crashed by 7728.68% in 2023 and then skyrocketed by 74166.63% in 2024.
  • Quarter analysis of 5 years shows BioNTech SE's Current Deferred Revenue stood at $212.9 million in 2021, then tumbled by 63.05% to $78.7 million in 2022, then soared by 445.08% to $428.8 million in 2023, then decreased by 26.5% to $315.1 million in 2024, then soared by 195.33% to $930.7 million in 2025.
  • Its Current Deferred Revenue was $930.7 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $309.8 million in Q1 2025.